Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Paul G Richardson, María-Victoria Mateos, Annette J Vangsted, Karthik Ramasamy, Niels Abildgaard, P Joy Ho, Hang Quach & Nizar J Bahlis. (2022) The role of E3 ubiquitin ligase in multiple myeloma: potential for cereblon E3 ligase modulators in the treatment of relapsed/refractory disease. Expert Review of Proteomics 19:4-6, pages 235-246.
Read now
Read now
Larysa Sanchez, Kevin Barley, Joshua Richter, Joseph Franz, Hearn Jay Cho, Sundar Jagannath, Deepu Madduri, Samir Parekh, Shambavi Richard & Ajai Chari. (2020) Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review. Expert Review of Hematology 13:9, pages 943-958.
Read now
Read now
Amanda S. Bruno, Jenny L. Willson, Joanna M. Opalinska, Jeanenne J. Nelson, Orsolya E. Lunacsek, Dana R. Stafkey-Mailey & Joanne P. Willey. (2020) Recent real-world treatment patterns and outcomes in US patients with relapsed/refractory multiple myeloma. Expert Review of Hematology 13:9, pages 1017-1025.
Read now
Read now
Paul G. Richardson, Sonja Zweegman, Elizabeth K. O’Donnell, Jacob P. Laubach, Noopur Raje, Peter Voorhees, Renda H. Ferrari, Tomas Skacel, Shaji K. Kumar & Sagar Lonial. (2018) Ixazomib for the treatment of multiple myeloma. Expert Opinion on Pharmacotherapy 19:17, pages 1949-1968.
Read now
Read now
Articles from other publishers (28)
Andreas Nikolaou, Cosmina Hogea, Yevgeniy Samyshkin, Eric M. Maiese, Leah Sansbury, Mustafa Oguz, Javier Cid-Ruzafa, Ritika Kapoor & Feng Wang. (2022) An Epidemiology Model for Estimating the Numbers of US Patients With Multiple Myeloma by Line of Therapy and Treatment Exposure. Value in Health 25:12, pages 1977-1985.
Crossref
Crossref
Sagar Lonial, Rakesh Popat, Cyrille Hulin, Sundar Jagannath, Albert Oriol, Paul G Richardson, Thierry Facon, Katja Weisel, Jeremy T Larsen, Monique C Minnema, Al-Ola Abdallah, Ashraf Z Badros, Stefan Knop, Edward A Stadtmauer, Yiming Cheng, Michael Amatangelo, Min Chen, Tuong Vi Nguyen, Alpesh Amin, Teresa Peluso & Niels W C J van de Donk. (2022) Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial. The Lancet Haematology 9:11, pages e822-e832.
Crossref
Crossref
Enrique M. Ocio, Carmen Montes-Gaisán, Gabriela Bustamante, Sebastián Garzón, Esther González, Ernesto Pérez, Maialen Sirvent, José María Arguiñano, Yolanda González, Rafael Ríos, Dunia de Miguel, Marta Grande, Alonso Fernández, Andrea Naves & Laura Rosiñol. (2022) Clinical and Sociodemographic Characteristics of Patients With Relapsed and/or Refractory Multiple Myeloma and Their influence on Treatment in the Real-World Setting in Spain: The CharisMMa Study. Clinical Lymphoma Myeloma and Leukemia 22:4, pages e241-e249.
Crossref
Crossref
Meletios A. Dimopoulos, Fredrik Schjesvold, Vadim Doronin, Olga Vinogradova, Hang Quach, Xavier Leleu, Yolanda Gonzalez Montes, Karthik Ramasamy, Alessandra Pompa, Mark-David Levin, Cindy Lee, Ulf Henrik Mellqvist, Roland Fenk, Hélène Demarquette, Hamdi Sati, Alexander Vorog, Richard Labotka, Jichang Du, Mohamed Darif & Shaji Kumar. (2022) Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial. Blood Cancer Journal 12:1.
Crossref
Crossref
Rafael Alonso & Juan José Lahuerta. (2022) Tumor Reduction in Multiple Myeloma: New Concepts for New Therapeutics. Frontiers in Oncology 11.
Crossref
Crossref
Catherine S. Y. Lecat, Jessica B. Taube, William Wilson, Jonathan Carmichael, Christopher Parrish, Gabriel Wallis, Charalampia Kyriakou, Lydia Lee, Shameem Mahmood, Xenofon Papanikolaou, Neil K. Rabin, Jonathan Sive, Ashutosh D. Wechalekar, Kwee Yong, Gordon Cook & Rakesh Popat. (2021) Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma. Frontiers in Oncology 11.
Crossref
Crossref
Iiro Toppila, Tatu Miettinen, Mariann I. Lassenius, Juha Lievonen, Melissa Bauer & Pekka Anttila. (2021) Characteristics and survival trends in Finnish multiple myeloma patients—a nationwide real-world evidence study. Annals of Hematology 100:7, pages 1779-1787.
Crossref
Crossref
Roman Hájek, Jiří Minařík, Jan Straub, Luděk Pour, Alexandra Jungova, Jesus G Berdeja, Mario Boccadoro, Lucie Brozova, Andrew Spencer, Frits van Rhee, Jorge Vela-Ojeda, Michael A Thompson, Rafat Abonour, Ajai Chari, Gordon Cook, Caitlin L Costello, Faith E Davies, Vania TM Hungria, Hans C Lee, Xavier Leleu, Noemi Puig, Robert M Rifkin, Evangelos Terpos, Saad Z Usmani, Katja C Weisel, Jeffrey A Zonder, Magda Bařinová, Matyáš Kuhn, Jiří Šilar, Lenka Čápková, Kenny Galvez, Jin Lu, Jennifer Elliott, Dawn Marie Stull, Kaili Ren & Vladimír Maisnar. (2021) Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. Future Oncology.
Crossref
Crossref
Evangelos Terpos, Joseph Mikhael, Roman Hajek, Ajai Chari, Sonja Zweegman, Hans C. Lee, María-Victoria Mateos, Alessandra Larocca, Karthik Ramasamy, Martin Kaiser, Gordon Cook, Katja C. Weisel, Caitlin L. Costello, Jennifer Elliott, Antonio Palumbo & Saad Z. Usmani. (2021) Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer Journal 11:2.
Crossref
Crossref
Jeff Sharman, Shaum M. Kabadi, Jamyia Clark & David Andorsky. (2020) Treatment patterns and outcomes among mantle cell lymphoma patients treated with ibrutinib in the United States: a retrospective electronic medical record database and chart review study. British Journal of Haematology 192:4, pages 737-746.
Crossref
Crossref
Yanfang Liu, Chao-Hsiun Tang, Hong Qiu, Sarah Siggins & Hsin-An Hou. (2021) Treatment pathways and disease journeys differ before and after introduction of novel agents in newly diagnosed multiple myeloma in Taiwan. Scientific Reports 11:1.
Crossref
Crossref
A. S. Rosenberg, A. Brunson, J. Tuscano, B. A. Jonas, R. Hoeg, T. Wun & T. H. M. Keegan. (2021) Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients. Blood Cancer Journal 11:1.
Crossref
Crossref
Yael C. Cohen, Albert Oriol, Ka Lung Wu, Noa Lavi, Philip Vlummens, Carolyn Jackson, Wendy Garvin, Robin Carson, Wendy Crist, Jiayu Fu, Huaibao Feng, Hong Xie, Jordan Schecter, Jesús San-Miguel & Sagar Lonial. (2021) Daratumumab With Cetrelimab, an Anti–PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 21:1, pages 46-54.e4.
Crossref
Crossref
Edin Basic, Mathias Kappel, Arpit Misra, Leopold Sellner, Boris A. Ratsch & Dennis A. Ostwald. (2020) Budget impact analysis of the use of oral and intravenous therapy regimens for the treatment of relapsed or refractory multiple myeloma in Germany. The European Journal of Health Economics 21:9, pages 1351-1361.
Crossref
Crossref
Sudhir Manda, Habte A. Yimer, Stephen J. Noga, Saulius Girnius, Christopher A. Yasenchak, Veena Charu, Roger Lyons, Jack Aiello, Kimberly Bogard, Renda H. Ferrari, Dasha Cherepanov, Brittany Demers, Vickie Lu, Presley Whidden, Suman Kambhampati, Ruemu E. Birhiray, Haresh S. Jhangiani, Ralph Boccia & Robert M. Rifkin. (2020) Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib. Clinical Lymphoma Myeloma and Leukemia 20:11, pages e910-e925.
Crossref
Crossref
Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Maria Roussou, Nikolaos Kanellias, Despina Fotiou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Maria Gavriatopoulou, Efstathios Kastritis & Meletios A. Dimopoulos. (2020) Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period. Annals of Hematology 99:6, pages 1257-1264.
Crossref
Crossref
Evangelos Terpos, Karthik Ramasamy, Nadjoua Maouche, Jiri Minarik, Ioannis Ntanasis-Stathopoulos, Eirini Katodritou, Matthew W. Jenner, Hana Plonkova, Maria Gavriatopoulou, Grant D. Vallance, Tomas Pika, Maria Kotsopoulou, Jaimal Kothari, Tomas Jelinek, Efstathios Kastritis, Robin Aitchison, Meletios A. Dimopoulos, Athanasios Zomas & Roman Hajek. (2020) Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. Annals of Hematology 99:5, pages 1049-1061.
Crossref
Crossref
Kodandaram PillarisettiSuzanne Edavettal, Mark MendonçaYingzhe LiMark Tornetta, Alexander BabichNate Majewski, Matt Husovsky, Dara ReevesEileen Walsh, Diana ChinLeopoldo LuistroJocelin JosephGerald ChuKathryn PackmanShoba Shetty, Yusri ElsayedRicardo AttarFrançois Gaudet. (2020) A T-cell–redirecting bispecific G-protein–coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood 135:15, pages 1232-1243.
Crossref
Crossref
Jia GUAN, Shiro TANAKA, Shuhei YAMADA, Izumi SATO & Koji KAWAKAMI. (2020) Treatment Patterns in Newly Diagnosed Multiple Myeloma Patients in Japan Using A Large-scale Claims Database： Retrospective Cohort Study. Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku 25:2, pages 43-53.
Crossref
Crossref
Thomas G. Martin, Kathryn Corzo, Marielle Chiron, Helgi van de Velde, Giovanni Abbadessa, Frank Campana, Malini Solanki, Robin Meng, Helen Lee, Dmitri Wiederschain, Chen Zhu, Alexey Rak & Kenneth C. Anderson. (2019) Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab. Cells 8:12, pages 1522.
Crossref
Crossref
Caitlin Costello, Faith E Davies, Gordon Cook, Jorge Vela-Ojeda, Jim Omel, Robert M Rifkin, Jesus Berdeja, Noemi Puig, Saad Z Usmani, Katja Weisel, Jeffrey A Zonder, Evangelos Terpos, Andrew Spencer, Xavier Leleu, Mario Boccadoro, Michael A Thompson, Dorothy Romanus, Dawn M Stull & Vania Hungria. (2019) INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma. Future Oncology 15:13, pages 1411-1428.
Crossref
Crossref
Sikander Ailawadhi, Maral DerSarkissian, Mei Sheng Duh, Marie-Hélène Lafeuille, George Posner, Stephen Ralston, Erin Zagadailov, Abbie Ba-Mancini & Robert Rifkin. (2019) Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma. Clinical Therapeutics 41:3, pages 477-493.e7.
Crossref
Crossref
Xavier Leleu, Thomas G. Martin, Hermann Einsele, Roger M. Lyons, Brian G.M. Durie, Karim S. Iskander & Sikander Ailawadhi. (2019) Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 19:1, pages 9-22.
Crossref
Crossref
Kari Remes, Pekka Anttila, Raija Silvennoinen, Mervi Putkonen, Hanna Ollikainen, Venla Terävä, Marjatta Sinisalo, Kristiina Kananen, Frida Schain, Päivi Castren-Kortegangas, Tiina M. Järvinen, Marta Pisini, Felix Wahl, Tricia Dixon & Amy Leval. (2018) Real-world treatment outcomes in multiple myeloma: Multicenter registry results from Finland 2009-2013. PLOS ONE 13:12, pages e0208507.
Crossref
Crossref
Meletios Dimopoulos, Michael Wang, Vladimir Maisnar, Jiri Minarik, William Bensinger, Maria-Victoria Mateos, Mihaela Obreja, Julie Blaedel & Philippe Moreau. (2018) Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. Journal of Hematology & Oncology 11:1.
Crossref
Crossref
Paul G. Richardson, Jesus F. San Miguel, Philippe Moreau, Roman Hajek, Meletios A. Dimopoulos, Jacob P. Laubach, Antonio Palumbo, Katarina Luptakova, Dorothy Romanus, Tomas Skacel, Shaji K. Kumar & Kenneth C. Anderson. (2018) Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer Journal 8:11.
Crossref
Crossref
Mohamad Mohty, Evangelos Terpos, Maria-Victoria Mateos, Michele Cavo, Sandra Lejniece, Meral Beksac, Mohamed Amine Bekadja, Wojciech Legiec, Meletios Dimopoulos, Svetlana Stankovic, Maria Soledad Durán, Valerio De Stefano, Alessandro Corso, Yulia Kochkareva, Edward Laane, Christian Berthou, Hans Salwender, Zvenyslava Masliak, Valdas Pečeliūnas, Wolfgang Willenbacher, João Silva, Vernon Louw, Damir Nemet, Zita Borbényi, Uri Abadi, Robert Schou Pedersen, Peter Černelč, Anna Potamianou, Catherine Couturier, Caroline Feys, Florence Thoret-Bauchet, Mario Boccadoro, Mohamed Bekadja, Rose-Marie Hamladji, Hocine Ait Ali, Selma Hamdi, Hadj Touhami, Nourredine Sidi Mansour, Wolfgang Willenbacher, Werner Linkesch, Damir Nemet, Robert Shou Pedersen, Niels Abildgaard, Edward Laane, Marju Hein, Mohamad Mohty, Jean Richard Eveillard, Abderrazak el Yamani, Philippe Moreau, Laurence Sanhes, Gérard Lepeu, Kamel Laribi, Eric Jourdan, Olivier Fitoussi, Olivier Allangba, Joël Fleury, Martine Escoffre, Riad Benramdane, Guillaume Cartron, Gérard Dine, Eric Legouffe, Hanns-Detlev Harich, Thomas Illmer, Steffen Dörfel, Carla Verena Hannig, Michael Koenigsmann, Gabriele Prange-Krex, Hans Salwender, Ingo Tamm, Wolfgang Zeller, Michael Maasberg, Rudolf Schlag, Martine Klausmann, Jens Uhlig, Burkhard Alkemper, Stefan Schütz, Hans-Werner Tessen, Benno Mohr, Peter Schmidt, Bernhard Heinrich, Holger Hebart, Gernot Seipelt, Thomas Zoeller, Frank Heits, Clemens Müller-Naendrup, Richard Hansen, Roland Repp, Ludwig Fischer Von Weikersthal, Rudolf Schmits, Jörg Heßling, B. Krammer-Steiner, Viktor Janzen, Michael Schauer, Marcus W. Grüner, Jens Kisro, Claudio Denzlinger, Werner Freier, Christian Junghanss, Martin Görner, Katharina Laichinger, Helmut Ostermann, Heinz Dürk, Georg Hess, Gernot Reich, Evangelos Terpos, Meletios Dimopoulos, Panagiota Matsouka, Anastasia Pouli, Achilles Anagnostopoulos, Tamas Masszi, Zita Borbényi, Janos Ivanyi, Arpad Szomor, Uri Abadi, Arnon Nagler, Hila Magen, Irit Avivi, Miriam Quitt, Antonio Palumbo, Mario Boccadoro, Valerio De Stefano, Tommaso Za, Daniele Vallisa, Roberto Foa, Alessandro Corso, Alberto Bosi, Angelo Vacca, Francesco Lanza, Giulia Palazzo, Giuseppe Avvisati, Michele Cavo, Felicetto Ferrara, Ugo Consoli, Maria Cantonetti, Emanuele Angelucci, Catello Califano, Francesco Di Raimondo, Attilio Guarini, Maurizio Musso, Michele Pizzuti, Nicola Giuliani, Antonio Ardizzoia, Nicola Di Renzo, Gianluca Gaidano, Alessandro Gozzetti, Vincenzo Pitini, Gabriella Farina, Riccardo Centurioni, Paolo De Fabritiis, Francesco Iuliano, Giorgio La Nasa, Giacinto La Verde, Fabrizio Pane, Umberto Recine, Maria La Targia, Giuseppe Mineo, Clotilde Cangialosi, Daniele Fagnani, Augusto Federici, Atelda Romano, Giorgina Specchia, Sergio Storti, Velia Bongarzoni, Andrea Bacigalupo, Marco Gobbi, Giancarlo Latte, Donato Mannina, Silvana Capalbo, Sandra Lejniece, Valdas Pečeliūnas, Mindaugas Jurgutis, Svetlana Stankovic, Wojciech Legiec, Dariusz Woszczyk, Jadwiga Hołojda, Slawomir Gornik, Andrzej Pluta, Elzbieta Morawiec-Szymonik, Slawomira Kyrcz-Krzemien, Wojciech Homenda, Sebastian Grosicki, Kazimierz Sulek, Andrzej Lange, Janusz Kloczko, Jolanta Starzak-Gwozdz, Andrzej Hellmann, Mieczyslaw Komarnicki, Kazimierz Kuliczkowski, Carolina Viveiros, Cristina Gonçalves, Natalia Esefyeva, Julia Kochkareva, Kamil Kaplanov, Elena Volodicheva, Elena Laricheva, Valentina Dergacheva, Marina Chukavina, Natalia Volchenko, Irina Nazarova, Ludmila Anchukova, Elena Ovanesova, Taras Gritsenko, Galina Salogub, Ludmila Magomedova, Irina Kuznetsova, Svetlana Osyunikhina, Olga Serdyuk, Elena Karyagina, Valentina Ivanova, Slovenia Peter Černelč, Vernon Louw, Corlia Coetzee, Karen Gunther, Dhayanithi Moodley, Soledad Duran, Asunción Echeveste Gutiérrez, Jaime Perez De Oteyza, Francisco Javier Capote, Maria Casanova, Jesus Martin Sanchez, Eduardo Rios-Herranz, Jeronima Ibañez-Garcia, Maria Jose Herranz, Belen Hernandez, Sara Sanchez Sanchez, Fernando Escalante, Fernando Carnicero, Joan Bargay Lleonart, Mercedes Gironella, Rafael Martínez, Ana Lopez De La Guia, Luis Palomera, Rebeca Iglesias, Fernando Solano Ramos, Javier De La Serna, Pedro Garcia Sanchez, Juan Besalduch Vidal, Maria-Victoria Mateos, Miguel Diaz Morfa, Turkey – Meral Beksac, Filiz Vural, Yildiz Aydin, Ali Unal, Hakan Goker, Oktay Bilgir, Birol Guvenc, Mehmet Turgut, Gulsum Gulistan Ozet, Ridvan Ali, Zvenyslava Masliak, Maryna Kyselyova, Nataliia Glushko, Renata Vybyrana, Igor Skrypnyk, Natalya Tretyak, Tetiana Kharchevska, Iryna Dyagil, Tetiana Popovs'ka, Vadim Shimanskiy, Tamila Lysa, Hanna Oliynyk, Kateryna Vilchevskaya, Iryna Kryachok, Yuriy Popovych, Natalia Romanyuk, Natalia Yushchenko, Polina Kaplan, Grygoriy Rekhtman, Halyna Pylypenko, Viktor Kozlov, Mohamad Mohty, Evangelos Terpos, Maria-Victoria Mateos, Antonio Palumbo, Johannes Drach, Mario Boccadoro, Jean-Luc Harousseau, Hermann Einsele, Hartmut Goldschmidt, Thierry Facon, Mauricette Michalet, Valery G. Savchenko, Javier De la Rubia, Gordon Cook, Ulf-Henrik Mellqvist & Heinz Ludwig. (2018) Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. Clinical Lymphoma Myeloma and Leukemia 18:10, pages e401-e419.
Crossref
Crossref
Jacob P. Laubach, Philippe Moreau, Meletios A. Dimopoulos & Paul G. Richardson. 2018. Multiple Myeloma and Other Plasma Cell Neoplasms. Multiple Myeloma and Other Plasma Cell Neoplasms
73
96
.